Megan E. Honeywell

p53 controls choice between apoptotic and non-apoptotic death following DNA damage.

Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy.

Functional genomic screens with death rate analyses reveal mechanisms of drug action.

Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy.

Pol II degradation activates cell death independently from the loss of transcription.